Eva Corey

Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases

J. Chirgwin, R. Vessella, L. Suva, 2006, Clinical Cancer Research.

Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Todd M Morgan, T. Morgan, E. Corey, 2009, Current cancer drug targets.

Prostatic cell lineage markers: Emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration

Franck Bladou, R. Vessella, P. Lange, 1996, International journal of cancer.

Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers

Stephen J. Salipante, Deborah A. Nickerson, Jay Shendure, 2011, Proceedings of the National Academy of Sciences.

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

Ming Yu, Colin C. Pritchard, Stephen J. Salipante, 2014, Nature Communications.

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

R. Vessella, E. Corey, L. Brown, 2006, BMC Cancer.

Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases

Lawrence D. True, Peter S. Nelson, Celestia S. Higano, 2007, Clinical & Experimental Metastasis.

Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts

R. Vessella, E. Corey, W. Olson, 2015, The Prostate.